CHI3L1 and acute respiratory distress syndrome: Recent research has obtained highly specific humanized CHI3L1 monoclonal antibodies through single-memory B-cell culture and achieved significant results in treating AILI, indicating the feasibility of CHI3L1 as a target for ALI treatment [100].